Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin (Adcetris), secukinumab (Cosentyx), and the secukinumab–interleukin 17A (IL-17A) drug-target complex. These sequence-defined antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for brentuximab vedotin, secukinumab, and their biosimilars.
Bio-Rad’s anti-brentuximab vedotin and anti-secukinumab inhibitory antibodies are available in Fab (fragment antigen-binding) and fully human IgG1 formats with different affinities. The antibodies can be used to develop PK bridging ELISAs to measure free drug or as a surrogate positive control or reference standard in an ADA assay.
Brentuximab vedotin is an antibody drug conjugate used to treat Hodgkin lymphoma by selectively targeting tumor cells expressing the CD30 antigen. The four new anti-brentuximab vedotin antibodies are specific to the ...
